Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nebivolol: a third-generation beta-adrenergic blocker.

Angie Veverka1, Donald S Nuzum, Jamie L Jolly

  • 1School of Pharmacy, Wingate University, NC 28174, USA. aveverka@wingate.edu

The Annals of Pharmacotherapy
|July 11, 2006
PubMed
Summary

Nebivolol, a novel beta-adrenergic blocker, effectively lowers blood pressure and shows promise for heart failure patients. Further research is needed to confirm long-term benefits and compare it with other beta-blockers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet.

The Annals of pharmacotherapy·2018
Same author

Oral ivermectin for the treatment of head lice infestation.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2018
Same author

Incorporating a Pharmacist Into the Discharge Process: A Unit-Based Transitions of Care Pilot.

Hospital pharmacy·2016
Same author

Creating and Assessing Student Perception of an Examination Mastery Score Report for a Pharmacotherapy Course.

American journal of pharmaceutical education·2016
Same author

Natural supplements for improving insulin sensitivity and glucose uptake in skeletal muscle.

Frontiers in bioscience (Elite edition)·2015
Same author

Improving pharmacist documentation of clinical interventions through focused education.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2014

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Nebivolol represents a third-generation beta-adrenergic blocker with unique vasodilatory properties.
  • Its pharmacokinetic and pharmacodynamic profiles are distinct from older beta-blockers.

Purpose of the Study:

  • To review the pharmacologic and pharmacokinetic properties of nebivolol.
  • To evaluate the efficacy of nebivolol in treating hypertension and heart failure through a literature review.

Main Methods:

  • Searches of MEDLINE and International Pharmaceutical Abstracts were conducted for studies on nebivolol.
  • Included preclinical studies and randomized, controlled clinical trials on hypertension and heart failure.

Main Results:

  • Nebivolol demonstrated comparable blood pressure-lowering effects to other antihypertensive therapies in short-term trials.

Related Experiment Videos

  • A long-term trial indicated significant reductions in death and cardiovascular hospital admissions in heart failure patients treated with nebivolol compared to placebo.

    • Conclusions:

    • Nebivolol is an effective antihypertensive agent and offers benefits for patients with heart failure.
    • Further studies are warranted to explore long-term hypertension benefits, comparative efficacy in heart failure, and the role of nitric oxide-mediated vasodilation.